From the Department of Rheumatology, Johns Hopkins University School of Medicine; the departments of Neurology, Anatomy, and Neurobiology, University of Maryland School of Medicine; the Veterans Affairs Medical Center, Baltimore, Maryland, USA.
B.L. Adler, MD, Rheumatology Fellow, Department of Rheumatology, Johns Hopkins University School of Medicine; J.W. Russell, MD, Professor of Neurology, departments of Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine and Veterans Affairs Medical Center; L.K. Hummers, MD, MSc, Associate Professor of Medicine, Department of Rheumatology, Johns Hopkins University School of Medicine; Z.H. McMahan, MD, MHS, Assistant Professor of Medicine, Department of Rheumatology, Johns Hopkins University School of Medicine.
J Rheumatol. 2018 Aug;45(8):1145-1152. doi: 10.3899/jrheum.170868. Epub 2018 Jun 15.
Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. We sought to quantify autonomic symptom burden in SSc, and to define the characteristics of patients with SSc and autonomic dysfunction.
Patients with SSc were consecutively recruited during routine clinical visits at the Johns Hopkins Scleroderma Center and asked to complete the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire, a validated tool to assess symptoms of autonomic dysfunction. We determined the relationship between various clinical and serological features of SSc and the total COMPASS-31 scores and domain-specific scores using the Student t test or Wilcoxon rank-sum test for dichotomous variables and linear regression analysis for continuous variables.
The study included 104 patients with SSc who completed the COMPASS-31 questionnaire. The mean COMPASS-31 score in this cohort was 24.9 ± 15.5, higher than COMPASS-31 scores from previously published healthy controls (8.9 ± 8.7). Compared to patients with mild or absent GI disease, patients with significant GI disease had higher scores across several subdomains of the COMPASS-31, including orthostatic intolerance (median 10.0 vs 0, p = 0.006) and secretomotor dysfunction (median 6.4 vs 4.3, p = 0.03). There was also a dose-response relationship between GI disease severity and autonomic symptom burden.
Symptoms of autonomic dysfunction are common in SSc. Patients with more severe GI disease in SSc report more symptoms of dysautonomia across many facets of the autonomic nervous system.
自主神经功能障碍是系统性硬化症(SSc)的已知并发症,可影响血管张力、胃肠(GI)动力、心率和血压控制。我们旨在量化 SSc 中的自主症状负担,并定义伴有自主神经功能障碍的 SSc 患者的特征。
在约翰霍普金斯硬皮病中心的常规临床就诊期间,连续招募 SSc 患者,并要求他们完成综合自主症状评分(COMPASS)-31 问卷,这是一种评估自主神经功能障碍症状的有效工具。我们使用学生 t 检验或二项变量的 Wilcoxon 秩和检验以及连续变量的线性回归分析,确定 SSc 的各种临床和血清学特征与总 COMPASS-31 评分和特定领域评分之间的关系。
该研究纳入了 104 名完成 COMPASS-31 问卷的 SSc 患者。该队列的平均 COMPASS-31 评分为 24.9 ± 15.5,高于先前发表的健康对照组的 COMPASS-31 评分(8.9 ± 8.7)。与 GI 疾病轻度或无的患者相比,GI 疾病严重的患者在 COMPASS-31 的多个亚域中评分更高,包括直立不耐受(中位数 10.0 与 0,p = 0.006)和分泌运动功能障碍(中位数 6.4 与 4.3,p = 0.03)。GI 疾病严重程度与自主症状负担之间也存在剂量反应关系。
自主神经功能障碍的症状在 SSc 中很常见。SSc 中 GI 疾病更严重的患者报告了自主神经系统许多方面的自主神经功能障碍症状更多。